Clinical trial NCT02257320: TMJ NextGeneration(TM) Feasibility Study
Official title: A Feasibility Study of the Bruxoff™ Device to Assess EMG Activity in Subjects Diagnosed With Sleep Bruxism Using TMJ NextGeneration(TM)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bruxism
Lead sponsor: Cardiox Corporation
Sponsor class: INDUSTRY
Collaborators: name: Cardiox Corporation
First posted: 2014-10-06
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study is an open-label, prospective, single-center, non-randomized feasibility study of the Bruxoff(TM) device to identify EMG activity associated with bruxism, and to assess the impact of the TMJ NextGeneration(TM) device upon the occurrence of night-time bruxism events and incidence of migraines and headache in subjects diagnosed with sleep bruxism.

Detailed description: The study will be conducted at one study center in the U.S. Subjects will be enrolled in the trial for a period of 8 weeks. The study will consist of a screening phase lasting up to 2 weeks and a follow up treatment period lasting 8 weeks. Subjects will visit the dental clinic twice during the screening period, then five times during the treatment period.

Eligibility criteria: Inclusion Criteria:

1. Subjects at least 18 years of age;
2. Subject has had a diagnosis of sleep bruxism;
3. Subject has been medically screened and diagnosed by a physician as having headaches and/or migraines;
4. Subject is willing to comply with the usage instructions for the Bruxoff device;
5. Is able to read and understand the ICF and has voluntarily provided written informed consent.
6. Subject is able to open their mouth at least 17 mm to be fitted for the TMJ NextGenerationTM device;
7. Male Subjects are willing to have a clean shaven face on the nights that the Bruxoff device will be used;
8. Subject agrees that when using the Bruxoff device to keep their cellular phone in another room.

Exclusion Criteria:

1. Subjects with any physical or behavioral disorder, which, in the opinion of the Principal Investigator, may interfere with the use of the device or compliance with the study protocol;
2. Subject has any sleep disorder other than bruxism;
3. Subjects who have had direct trauma to the jaw;
4. Subjects who have had prior TMJ or ear surgery;
5. Subjects who have a narrow ear canal or impression of the ear canal, which is prolapsed due to an anatomical shift or failure of the ear canal wall structure, or a canal that does not allow for the ear canal second turn to be identified;
6. Subjects with visible or congenital ear deformity as observed on targeted physical exam;
7. Subjects whose ear canal anatomy does not allow for fit of the study device;
8. Subjects who have a history of ear pain unrelated to TMJ;
9. Subjects who have a history of ear drainage in the past 6 months;
10. Subjects who have active ear drainage, swelling, or redness as observed on targeted physical exam;
11. Subject has experienced chronic pain (not including migraine pain) associated with sleep bruxism or TMD for more than six months;
12. Subject has a pacemaker.

Primary outcomes:
measure: Effectiveness of Bruxoff(TM) to measure EMG activity in bruxing subjects using the TMJ NextGeneration(TM) device.
timeFrame: baseline and 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Boca Raton
country: United States
facility: Ear, Nose and Throat Associates of South Florida
state: Florida
city: Boynton Beach
country: United States
facility: Ear, Nose and Throat Associates of South Florida
state: Florida
Study officials:
affiliation: Cardiox Corporation
name: simon blackburn
role: STUDY_DIRECTOR
References: